Is ALS Incidence Increasing?
Yes, ALS incidence is rising globally, driven primarily by population aging and improved case ascertainment, with projections showing continued increases through 2040.
Evidence of Rising Incidence
The most robust recent data demonstrates a clear upward trend:
Denmark (1980-2021): The incidence rate increased 2.8-fold over 42 years, rising from the earliest period (1980-1983) to the most recent (2018-2021), with parallel increases in mortality rates 1. This represents one of the longest population-based studies available.
United States projections: Administrative claims data from over 100 million patients shows both incident and prevalent cases are increasing, with predictive modeling demonstrating continued growth through 2060 2. State-level data from 2012-2019 shows overall U.S. incidence of 1.44 per 100,000 persons, with regional variation 3.
Global meta-analysis: Worldwide incidence has been significantly rising year-by-year since 1957, though this upward trend weakens after age-standardization 4.
Primary Drivers of the Increase
Population Aging (Main Factor)
The increase is predominantly explained by demographic shifts rather than new environmental exposures:
- Peak ALS incidence occurs in the 70-79 age group 1
- The 66+ age group will see a 25% increase in ALS cases from 2022 to 2030 in the U.S. 5
- Italian data (1964-1998) showed incidence increases were greatest in individuals ≥70 years old, correlating with substantial population aging 6
Improved Case Ascertainment
Better diagnostic precision contributes to apparent increases:
- Enhanced recognition of ALS in elderly patients, particularly women 6
- More comprehensive case identification through national registries 3
- The age-period-cohort analysis from Ireland shows emerging period effects (increasing incidence in recently diagnosed groups) but no cohort effect, suggesting diagnostic improvements over true disease increase 7
Future Projections
ALS prevalence will increase substantially:
- Italy: Projected to reach 15.72 per 100,000 by 2040 (from current baseline) 8
- Global median increase: 24.9% across multiple countries by 2040 8
- U.S. cases: Expected to rise from 32,893 (2022) to 36,308 (2030), representing a >10% increase 5
Impact of Therapeutic Advances
If new treatments extend survival by just 6 months starting in 2025, prevalence would increase by 37.8% by 2040 8, as longer survival means more living patients at any given time.
Clinical Implications
This is no longer a "rare" disease in aging populations 8. The convergence of:
- Aging demographics (primary driver)
- Improved survival from emerging therapeutics
- Better diagnostic capabilities
...means healthcare systems must prepare for substantially increased ALS patient volumes. The 2024 NASEM report emphasizes urgent need for expanded multidisciplinary care infrastructure, Medicare eligibility expansion, and caregiver support systems 9.
Important Caveats
- Age-standardization matters: When controlling for population age structure, the increase is less dramatic, confirming aging as the dominant factor 4, 6
- Geographic variation exists: New England and upper Midwest U.S. regions show higher incidence than national averages 3
- Environmental factors: While population aging explains most of the trend, environmental contributions cannot be entirely excluded but appear less important 6
The evidence consistently points to a true increase in absolute case numbers, making resource allocation and care system planning critical priorities for the coming decades.